3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Enrolling by invitation
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Interventions
Educational Status
5
Interviews as Topic
4
Methods
3
Magnetic Resonance Imaging
3
Early Intervention, Educational
3
Cisplatin
3
Blood Specimen Collection
3
pembrolizumab
2
Standard of Care
2
Nivolumab
2
Music Therapy
2
Gemcitabine
2
Counseling
2
zilucoplan
1
tislelizumab
1
somapacitan
1
sacituzumab govitecan
1
rozanolixizumab
1
oxycodone-acetaminophen
1
ibrutinib
1
futibatinib
1
fluorodopa F 18
1
erdafitinib
1
enzalutamide
1
enfortumab vedotin
1
dynorphin-converting endopeptidase
1
durvalumab
1
dalpiciclib
1
brexucabtagene autoleucel
1
axicabtagene ciloleucel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Enrolling by invitation
×
zilucoplan
×
90 days
×
Clear all
NCT06435312
2026-05-08
ziMyG+
UCB Pharma
Phase 3
Enrolling by invitation
8 enrolled